<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6917977\results\search\tropicalVirus\results.xml">
  <result pre="non�?commercial and no modifications or adaptations are made.file:PBI-18-266.pdf Abstract Summary" exact="Chikungunya" post="virus (CHIKV) is a mosquito�?transmitted alphavirus, and its infection"/>
  <result pre="no licensed vaccines or therapeutics for human use to combat" exact="CHIKV" post="infections. In this study, we explored the feasibility of"/>
  <result pre="wild�?type (WT) and glycoengineered (∆XFT) Nicotiana benthamiana plants in treating" exact="CHIKV" post="infection in a mouse model. CHIKV mAb was efficiently"/>
  <result pre="benthamiana plants in treating CHIKV infection in a mouse model." exact="CHIKV" post="mAb was efficiently expressed and assembled in plant leaves"/>
  <result pre="plants as an effective platform for production of functionally active" exact="CHIKV" post="mAbs and implies optimization of in vivo activity by"/>
  <result pre="and Infectious Diseases 10.13039/100000060 R33AI101329R15A113706R15AI135893 fig-count: table-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) is a positive�?sense RNA virus belonging to"/>
  <result pre="2 (E1 and E2) (Voss et al., 2010). Infection of" exact="CHIKV" post="in humans can cause debilitating polyarthralgia that may persist"/>
  <result pre="knees, wrists and fingers (Schilte et al., 2013). Since 2004," exact="CHIKV" post="reemergence has resulted in millions of cases of severe"/>
  <result pre="2015). Currently, there are no licensed therapeutics or vaccines against" exact="CHIKV" post="for human use. Continued outbreaks of CHIKV and the"/>
  <result pre="or vaccines against CHIKV for human use. Continued outbreaks of" exact="CHIKV" post="and the risk of it spreading into new areas"/>
  <result pre="show evidence of protectivity, as these subjects are immune to" exact="CHIKV" post="reinfection (Kam et al., 2012; Yoon et al., 2015)."/>
  <result pre="2012; Yoon et al., 2015). Indeed, monoclonal antibodies (mAbs) against" exact="CHIKV" post="E1 and E2 have been shown to be protective"/>
  <result pre="E1 and E2 have been shown to be protective against" exact="CHIKV" post="infection in various mouse models. For example, anti�?E1 or"/>
  <result pre="protected immune compromised (Ifnar �?/�?) mice against lethal challenges of" exact="CHIKV" post="when given as post�?exposure therapy (Pal et al., 2013)."/>
  <result pre="candidates to treat various viral infections including those caused by" exact="West Nile" post="virus (WNV) (Sun et al., 2018), dengue virus (DENV)"/>
  <result pre="incompletely processed and oligomannosidic structures. Both mAb variants potently neutralized" exact="CHIKV" post="in vitro. Notably, both pCHKVmab glycoforms also showed efficacy"/>
  <result pre="pCHKVmab glycoforms also showed efficacy but with different potency against" exact="CHIKV" post="infection in a murine model. Results Expression and assembly"/>
  <result pre="Wiley &amp;amp; Sons, Ltd, Neutralization activity of plant�?derived CHKVmab against" exact="CHIKV" post="Plaque reduction neutralization test (PRNT) was used to evaluate"/>
  <result pre="used to evaluate the neutralization potential of plant�?produced mAbs against" exact="CHIKV" post="(Yang et al., 2017b). While the negative control mAb"/>
  <result pre="CHIKV, both WTpCHKVmab and ∆XFpCHKVmab showed strong neutralizing activity against" exact="CHIKV" post="with statistically similar potency (∆XFpCHKVmab EC50 = 130.5 ng/mL"/>
  <result pre="mAb (∆XFpWNVmab, negative control) were co�?incubated with 100 PFU of" exact="CHIKV" post="and Vero cells for 3 days. Plaques were counted,"/>
  <result pre="of the mean. In vivo efficacy of plant�?derived CHKVmab against" exact="CHIKV" post="infection Among mouse models of CHIKV infection, WT mice"/>
  <result pre="of plant�?derived CHKVmab against CHIKV infection Among mouse models of" exact="CHIKV" post="infection, WT mice (i.e. WT C57BL/6) develop arthritis symptoms"/>
  <result pre="in the right footpad with 1 × 105 PFU of" exact="CHIKV" post="and then treated at 12 h post�?infection with 50"/>
  <result pre="and post�?exposure therapeutics for CHIKV. Figure 4 Plant�?produced CHKVmabs reduce" exact="CHIKV" post="viraemia in mice. Wild�?type C57BL/6J mice (N = 6"/>
  <result pre="group) were subcutaneously infected with 1 × 105 PFUs of" exact="CHIKV" post="and treated intraperitoneally with 50 μg of indicated CHKVmab"/>
  <result pre="at day 2 dpi is presented as a ratio of" exact="CHIKV" post="E1 copy number per 1000 copy of cellular β�?actin."/>
  <result pre="determined by t�?tests. Antibody�?dependent enhancement activity of plant�?produced CHKVmab for" exact="DENV" post="infection One of the challenges for mAb therapeutics against"/>
  <result pre="For example, cross�?reactive but sub�?neutralizing antibodies against one serotype of" exact="DENV" post="from a previous infection can form complexes with another"/>
  <result pre="a previous infection can form complexes with another serotype of" exact="DENV" post="during a secondary infection to promote viral infection of"/>
  <result pre="ADE (Sun et al., 2018). Since the E proteins of" exact="CHIKV" post="and DENV are related and the two viruses co�?circulate"/>
  <result pre="et al., 2018). Since the E proteins of CHIKV and" exact="DENV" post="are related and the two viruses co�?circulate geographically (Kam"/>
  <result pre="cross�?reacts with E of most flaviviruses, efficiently caused ADE of" exact="DENV" post="infection in K562 cells that express the human FcγR"/>
  <result pre="In contrast, ∆XFpCHKVmab and WTpCHKVmab did not promote ADE for" exact="DENV" post="(Figure 5). These results indicate that plant�?produced CHKVmabs are"/>
  <result pre="not only efficacious but also safe as potential treatment against" exact="CHIKV" post="infection. Figure 5 Antibody�?dependent enhancement of CHKVmabs for DENV"/>
  <result pre="against CHIKV infection. Figure 5 Antibody�?dependent enhancement of CHKVmabs for" exact="DENV" post="infection. Serial dilutions of CHKVmabs or 4G2 (positive control"/>
  <result pre="and analysed by flow cytometry. Discussion The expanding epidemics of" exact="CHIKV" post="demand the development of efficacious therapeutics against this debilitating"/>
  <result pre="mouse anti�?CHIKV mAbs indicate that some of the antibodies against" exact="CHIKV" post="E1 and E2 have protective activity and their protectivity"/>
  <result pre="the feasibility of using plant�?produced mAbs against E1 in treating" exact="CHIKV" post="infection in a mouse model as a step towards"/>
  <result pre="mouse model as a step towards improving the efficacy of" exact="CHIKV" post="immunotherapy in humans. A prerequisite for plant�?made mAbs to"/>
  <result pre="manufacturing of CHKVmabs. Together, these results indicate that similar to" exact="CHIKV" post="vaccine development (Cardona�?Ospina et al., 2016; Salazar�?Gonzalez et al.,"/>
  <result pre="and cost, which will markedly increase the affordability of mAb�?based" exact="CHIKV" post="drugs to people in the developing world, where the"/>
  <result pre="to people in the developing world, where the majority of" exact="CHIKV" post="cases occurs. Another striking feature of the plant transient"/>
  <result pre="et al., 2013). Plant�?made CHKVmab exhibited strong neutralizing activity against" exact="CHIKV" post="with potencies similar to mammalian cell�?derived CHKVmab (Pal et"/>
  <result pre="compromised (Ifnar �?/�? or AG129) mice are subject to lethal" exact="CHIKV" post="infection, providing a convenient survival model (Pal et al.,"/>
  <result pre="do not develop the arthritis observed in humans. In contrast," exact="CHIKV" post="infection in WT C57BL/6 mice causes arthritis and swelling"/>
  <result pre="2017), presenting a more relevant animal model for studying human" exact="CHIKV" post="infection. CHIKV infection in WT C57BL/6 mice does not"/>
  <result pre="a more relevant animal model for studying human CHIKV infection." exact="CHIKV" post="infection in WT C57BL/6 mice does not cause lethal"/>
  <result pre="results showed that ∆XFpCHKVmab had better in vivo efficacy against" exact="CHIKV" post="than WTpCHKVmab. These results support our hypothesis that some"/>
  <result pre="addition, neither of the two mAb glycoforms promoted ADE for" exact="DENV" post="infection. These results suggest that mAbs have the potential"/>
  <result pre="to be used as effective and safe prophylaxis to prevent" exact="CHIKV" post="infection during outbreaks, especially for populations with high risk"/>
  <result pre="studies in mouse arthritis models that mimic symptoms of human" exact="CHIKV" post="infection. In the context of recent studies that demonstrate"/>
  <result pre="of recent studies that demonstrate broadly neutralizing human mAbs against" exact="CHIKV" post="E2 with therapeutic activity (Smith et al., 2015), our"/>
  <result pre="the development of a novel multi�?target therapy to combat sudden" exact="CHIKV" post="outbreaks. Materials and methods Ethics statement and biosafety All"/>
  <result pre="(USM). All in vitro experiments and animal studies involving live" exact="CHIKV" post="were performed by the certified personnel in the USM"/>
  <result pre="and purified with a method previously developed for anti�?WNV and" exact="DENV" post="mAbs (Dent et al., 2016; Lai et al., 2010,"/>
  <result pre="(http://www.proglycan.com) was used to annotate the glycans. Virus and cells" exact="CHIKV" post="(strain LR�?OPY1, kindly provided by Dr. Robert B. Tesh"/>
  <result pre="FBS at 37 °C in an incubation with 5% CO2." exact="CHIKV" post="neutralization and plaque assay Plaque reduction neutralization test (PRNT)"/>
  <result pre="Specifically, mAbs were serially diluted in phosphate�?buffered saline (PBS), while" exact="CHIKV" post="was diluted in serum�?free DMEM to a working concentration"/>
  <result pre="units (PFUs) per well. Following dilutions, mAbs were added to" exact="CHIKV" post="and incubated for 1 h at 37 °C. CHIKV�?mAb"/>
  <result pre="and counted. Percent (%) neutralization was calculated as: [(number of" exact="CHIKV" post="plaque per well with no mAb) − (number of"/>
  <result pre="CHIKV plaque per well with no mAb) − (number of" exact="CHIKV" post="plaque per well of diluted mAb)/(number of CHIKV plaque"/>
  <result pre="(number of CHIKV plaque per well of diluted mAb)/(number of" exact="CHIKV" post="plaque per well with no mAb) × 100]. Experiments"/>
  <result pre="side of the right hind footpad with 105 PFUs of" exact="CHIKV" post="as previously described (Acharya et al., 2015). Mice were"/>
  <result pre="was synthesized by using the iSCRIPT cDNA synthesis kit (Bio�?Rad)." exact="CHIKV" post="envelope protein 1 (CHIKV E1) and cellular β�?actin RNA"/>
  <result pre="(Bio�?Rad). Viral copy numbers were expressed as the ratio of" exact="CHIKV" post="E1 to cellular β�?actin. Primer sequences for mouse β�?actin"/>
  <result pre="E1 to cellular β�?actin. Primer sequences for mouse β�?actin and" exact="CHIKV" post="E1 gene were previously described (Acharya et al., 2015)."/>
  <result pre="assay The potential enhancing activities of the anti�?CHIKV mAbs for" exact="DENV" post="infection were examined by using FcγRIIa+ K562 cells (ATCC,"/>
  <result pre="B. Tesh at University of Texas Medical Branch for providing" exact="CHIKV" post="strain and Collin Jugler for the critical reading of"/>
  <result pre="Plant expression systems, a budding way to confront chikungunya and" exact="Zika" post="in developing countries?F1000Res, 5, 2121.27781090 Chen, Q. (2016) Glycoengineering"/>
  <result pre="M.S.et al (2010) Monoclonal antibody produced in plants efficiently treats" exact="West Nile" post="virus infection in mice. Proc. Natl. Acad. Sci. USA,"/>
  <result pre="Chen, Q. (2018) A plant�?produced vaccine protects mice against lethal" exact="West Nile" post="virus infection without enhancing Zika or dengue virus infectivity."/>
  <result pre="protects mice against lethal West Nile virus infection without enhancing" exact="Zika" post="or dengue virus infectivity. Vaccine, 36, 1846–1852.29490880 Leuzinger, K.,"/>
  <result pre="4, 419–425.22699226 Salazar�?Gonzalez, J.A., Angulo, C. and Rosales�?Mendoza, S. (2015)" exact="Chikungunya" post="virus vaccines: Current strategies and prospects for developing plant�?made"/>
  <result pre="Madec, Y., Carpentier, F., Kassab, S., Albert, M.L.et al (2013)" exact="Chikungunya" post="virus�?associated long�?term arthralgia: a 36�?month prospective longitudinal study. PLoS"/>
  <result pre="C., Crublet, E., Thompson, A.et al (2010) Glycoprotein organization of" exact="Chikungunya" post="virus particles revealed by X�?ray crystallography. Nature, 468, 709.21124458"/>
  <result pre="Lai, H., Sun, H. and Chen, Q. (2017a) Immunization of" exact="Zika" post="virus envelope protein domain III induces specific and neutralizing"/>
  <result pre="protein domain III induces specific and neutralizing immune responses against" exact="Zika" post="virus. Vaccine, 35, 4287–4294.28669618 Yang, M., Lai, H., Sun,"/>
  <result pre="Sun, H. and Chen, Q. (2017b) Virus�?like particles that display" exact="Zika" post="virus envelope protein domain III induce potent neutralizing immune"/>
  <result pre="H., Lai, H., Hurtado, J. and Chen, Q. (2018) Plant�?produced" exact="Zika" post="virus envelope protein elicits neutralizing immune responses that correlate"/>
  <result pre="elicits neutralizing immune responses that correlate with protective immunity against" exact="Zika" post="virus in mice. Plant Biotechnol. J.16, 572–580.28710796 Yoon, I.K.,"/>
 </snippets>
</snippetsTree>
